Therapeutics News and Research

RSS

New UK SARS-CoV-2 variant circulating in US since November, says study

A new study by researchers at the Department of Ecology and Evolutionary Biology, University of Arizona, showed that the new variant has circulated in the US since November.

26 Jan 2021

New partnership to develop test for predicting disease course in pediatric Crohn's patients

The Crohn's & Colitis Foundation, the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), has entered into a partnership with LifeArc, an independent medical research charity that advances translation of early science into health care treatments or diagnostics, to potentially develop the first clinical lab test to predict disease course in pediatric patients with Crohn's disease and response to treatment.

25 Jan 2021

Probiotics as adjuvant therapy for COVID-19 patients

In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.

25 Jan 2021

New SARS-CoV-2 variants resistant to convalescent sera and and monoclonal antibodies

Researchers studying the effect of convalescent sera and monoclonal antibodies from recovered patients found the UK and South African SARS-CoV-2 variants are more resistant to neutralization compared to the wild-type virus.

25 Jan 2021

Newly designed Biomesh minimizes postsurgical complications of hernia repair

Hernias are one of the most common soft tissue injuries. Hernias form when intra-abdominal content, such as a loop of the intestine, squeezes through weak, defective or injured areas of the abdominal wall.

25 Jan 2021

George Mason researchers investigating COVID-19 therapies

Yuntao Wu, Professor, Molecular and Microbiology, and Ramin Hakami, Associate Professor, School of Systems Biology, are conducting studies of COVID-19 therapies.

22 Jan 2021

Treating 'fetus as the patient' could reduce the incidence of pre-term labor and premature birth

The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the 'fetus as the patient'.

22 Jan 2021

New project to investigate a promising drug target for treatment of schizophrenia

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the treatment of schizophrenia.

22 Jan 2021

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

A new study by US-based researchers shows the presence of protective antibodies that target the N-terminal domain (NTD) of the spike instead of the spike receptor-binding domain (RBD).

22 Jan 2021

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Researchers provide an overview of SARS-CoV-2 and its life cycle pathways, addressing the functional changes in the viral proteins, providing important strategic clues to help that may help in the ongoing development of therapies against COVID-19.

22 Jan 2021

Study identifies a host of agents with anti-SARS-CoV-2 potential

A team of researchers at the Genomics Research Center, Academia Sinica, in Taiwan, evaluated the efficacy of 2,855 agents against SARS-CoV-2.

22 Jan 2021

Mitochondrial mutation linked to elevated diabetes risk in Japanese men

A new study of Type 2 diabetes in Japanese populations has uncovered a previously uncharacterized genetic variant that puts male carriers at greater risk for the disease, as well as the mechanism by which it does so.

21 Jan 2021

New model shows key role of innate immunity in controlling COVID-19 viral load

Since SARS-CoV-2 was identified in December 2019, researchers have worked feverishly to study the novel coronavirus. Although much knowledge has been gained, scientists still have a lot to learn about how SARS-CoV-2 interacts with the human body, and how the immune system fights it.

21 Jan 2021

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.

21 Jan 2021

South African SARS-CoV-2 variant escapes antibody neutralization

Researchers in South Africa have conducted a study showing that the novel 501Y.V2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in the country is able to escape the neutralizing antibodies that are elicited by previously circulating strains of the virus.

20 Jan 2021

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

20 Jan 2021

Patients fend for themselves to access highly touted covid antibody treatments

By the time he tested positive for covid-19 on Jan. 12, Gary Herritz was feeling pretty sick. He suspects he was infected a week earlier, during a medical appointment in which he saw health workers who were wearing masks beneath their noses or who had removed them entirely.

20 Jan 2021

BMP5/7 protein offers promising therapeutics that could halt the progression of Parkinson's disease

Ben-Gurion University of the Negev researchers have discovered that the protein BMP5/7 offers promising therapeutics that could slow down or halt the progression of Parkinson's disease.

20 Jan 2021

Scientists uncover elusive mechanism behind the most severe cases of blood disorder

With a name like glucose-6-phosphate dehydrogenase deficiency, one would think it is a rare and obscure medical condition, but that's far from the truth.

19 Jan 2021

Carbon-based nanomaterials as potential COVID-19 treatments

An international team of researchers says that carbon-based nanomaterials (CBNs) could represent promising new approaches to treating coronavirus disease 2019 (COVID-19) pneumonia that is complicated by a secondary bacterial, viral or fungal infection.

19 Jan 2021

Therapeutics News and Research

New UK SARS-CoV-2 variant circulating in US since November, says study

New partnership to develop test for predicting disease course in pediatric Crohn's patients

Probiotics as adjuvant therapy for COVID-19 patients

New SARS-CoV-2 variants resistant to convalescent sera and and monoclonal antibodies

Newly designed Biomesh minimizes postsurgical complications of hernia repair

George Mason researchers investigating COVID-19 therapies

Treating 'fetus as the patient' could reduce the incidence of pre-term labor and premature birth

New project to investigate a promising drug target for treatment of schizophrenia

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Study identifies a host of agents with anti-SARS-CoV-2 potential

Mitochondrial mutation linked to elevated diabetes risk in Japanese men

New model shows key role of innate immunity in controlling COVID-19 viral load

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

South African SARS-CoV-2 variant escapes antibody neutralization

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Patients fend for themselves to access highly touted covid antibody treatments

BMP5/7 protein offers promising therapeutics that could halt the progression of Parkinson's disease

Scientists uncover elusive mechanism behind the most severe cases of blood disorder

Carbon-based nanomaterials as potential COVID-19 treatments

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News